Re: Christan Walter, Bilal Al-Nawas, Knut A. Grötz, et al. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 2008;54:1066-72

Eur Urol. 2009 Mar;55(3):e61-2. doi: 10.1016/j.eururo.2008.10.018. Epub 2008 Oct 16.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Bone Density Conservation Agents / adverse effects*
  • Diphosphonates / adverse effects*
  • Humans
  • Imidazoles / adverse effects*
  • Jaw Diseases / chemically induced*
  • Jaw Diseases / epidemiology
  • Male
  • Osteonecrosis / chemically induced*
  • Osteonecrosis / epidemiology
  • Prevalence
  • Prostatic Neoplasms / drug therapy*
  • Risk Factors
  • Zoledronic Acid

Substances

  • Bone Density Conservation Agents
  • Diphosphonates
  • Imidazoles
  • Zoledronic Acid